Daniella Kranjac is a Co-Founder and Managing Partner at Dynamk Capital, a venture capital fund investing in Life Sciences companies to accelerate their growth and technology adoption of disruptive solutions and services. Our portfolio companies innovate the tools, technologies and services that enable the discovery, development and production of life-saving therapies and deliver on the biopharmaceutical industry's evolution towards lower costs, and increased access to medicines globally.
Daniella has deep domain experience in life sciences as an entrepreneur, corporate executive, advisor and investor. She began her career as a Co-Founder of Wave Biotech LLC where she drove the growth of a disruptive technology, building the company to over $30 million in revenue and leading the group to a successful exit and acquisition by GE Healthcare in 2007. Wave Biotech was awarded BioProcess International’s Technology of the Decade Award. At GE, Daniella held several strategic, business development, M&A and commercial leadership roles, creating a several hundred-million-dollar Enterprise Solutions business, and was awarded the GE Healthcare Leadership award in 2015.
Daniella currently serves on the boards of Envisagenics, FloDesign Sonics and Stevens Institute of Technology, where she is a Charter Member of the Board of Trustees.
She holds a B.E. in Chemical Engineering from Stevens Institute of Technology and an Executive MBA from New York University Stern School of Business and has attended Harvard Business School Executive Education Courses in Private Equity & Venture Capital.